Biliary excretion of Olsalazine sodium in humans
- 11 Downloads
The biliary excretion of Olsalazine sodium (ADS) was studied by three different methods in healthy volunteers and in patients. 1 g ADS in a 2% solution was infused during 1 h into jejunum in six healthy volunteers via a three lumen sond. The bile was collected, during 2.5–6 h, proximal of an occlusive balloon on the three lumen sond. 10 mg ADS was given i.v. to five healthy volunteers and the bile was collected during 3–4.5 h with the same type of three lumen sond as used in the first experiment. 1 g ADS was given orally to three patients, with a T-tube inserted into coleducus at surgery. The bile was collected via the T-tube for 24 h.
The mean biliary excretion of the jejunal dose was 0.41% (0.22% if one subject, who probably had a beckflow of the instillation fluid, is omitted). In patients, the mean excretion with bile of ADS was 0.35% and of ac-5-ASA 0.17%. Due to the short collection time after jejunal infusion and the probably incomplete collection of bile in both enteral studies the biliary excretion was estimated to be less than 2% as ADS and less than 1% as ac-5-ASA.
The biliary excretion of an i.v. dose showed large individual variations (0.16–12.2%) which were not correlated to the length of the collection time. The total excretion was estimated to be less than 20% as ADS. No metabolites were detected after the i.v. dose.
Key wordsOlsalazine sodium piNN DipentumTM ADS azodisalsodium human bile excretion
Unable to display preview. Download preview PDF.
- 1.Azad Khan A.K., (1977): Lancet. An experiment to determine the active therapeutic moiety of sulphasalazine, ii, 892–895.Google Scholar
- 2.van Hees P.A.M., Bakker J.H., van Tongeren J.H.M., (1980): Gut. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine,21, 632–635.Google Scholar
- 3.Campieri M., Lanfranchi G.A., Bazzocchi G., Brignola C, Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P.R., (1981): Lancet. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas,2, 270–271.Google Scholar
- 4.Klotz U., Maier K., Fischer C, Heinkel K., (1980): N. Eng. J. Med. Therapeutic efficacy of sulphasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease,303, 1499–1502.Google Scholar
- 5.Selby W.S., Barr G.D., Ireland A., Mason CH., Jewell D.P., (1985): Br. Medical J. Olsalazine in active ulcerative colitis,291, 1373–1375.Google Scholar
- 6.Hetzel D.J., Shearman D.J.C, Bochner F., Imhoff D.M., Gibson G.E., Fitch R.J., Hecker R., LaBrooy J., Rowland R., Manuscript. Azodisalicylate (ADS) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition.Google Scholar
- 7.Sandberg-Gertzén H., Järnerot G., Kraaz W., (1986): Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse prevention properties Gastroenterology90, 1024–1030.Google Scholar
- 8.Bodin N-O. (Personnal communication).Google Scholar
- 9.Rollins D.E., Klaassen CD., (1979): Clinical Pharmacokinetics. Biliary Excretion of Drugs in Man,4, 368–379.Google Scholar
- 10.Brogard J.M., Arnaud J.P., Blicklé J.F., Lavillaureix J., (1984): Antimicrob. Agents Chemother. Biliary Elimination of Apalcillin in humans,26, 428–430.Google Scholar
- 11.Davenport H.W., (1971): Year Book Medical Publ. Incorp. Secretion of the Bile. Third edition, 129–138.Google Scholar
- 12.Davidson J.S., (1984): Physiology of Extrahepatic Bile Transport in Textbook of Gastroenterology. Ed:s Bouchier I.A.D., Allan R.N., Hodgson H.J.F., Keighley M.R.B., Balliere Tindall, 1376–1380.Google Scholar
- 13.Peeters T.L., Vantrappen G., Janssens, (1980): Gastroenterology. Bile Acid Output and the Interdigestive Migration Motor Complex in Normals and in Cholesystectomy Patients,79, 678–681.Google Scholar
- 14.Svenberg T., Christofides N.D., Fitzpatrick M.L., Areola-Ortiz F., Bloom S.R., Welbourn R.B., (1982): Gut. Interdigestive Biliary Output in Man: Relationship to fluctuations in plasma motilin and effect of atropine,23, 1024–1028.Google Scholar
- 15.van Hogezand R.A., van Hees P.A.M., Zwaneburg B., van Rossum J.M., van Tongeren J.H.M., (1985): Gastroenterology. Disposition of Disodium Azodisalicylate in Healthy Subjects. A possible New Drug for Inflammatory Bowel Disease,88, 717–722.Google Scholar
- 16.Ryde M. Manuscript. The pharmacokinetics of Olsalazine sodium in healthy volunteers after single i.v. dose, oral dose with and without food and increasing oral doses within a possible therapeutic range.Google Scholar
- 17.Brogard J.M., Kopferschmitt J., Arnaud J.P., Dorner M., La ViUaureix J., (1980): Antimicrobiol. Agents and Chemotherapy. Biliary Elimination of Mezlocillin: An Experimental and Clinical Study,18, 69–76.Google Scholar
- 18.Gundert-RemyU., Weber E., (1982): Eur. J. Pharmacol. Elimination of Azlocillin in Patients with Biliary t-tube Drainage, 435–439.Google Scholar
- 19.Brogard J.M., Jehl F., Arnaud J.P., Lévy P., Pealadan F., Blicklé J.F., Monteil H., (1985): Scweiz. med. Wschr. Ciprofloxacine: évaluation de son éliminations biliare chez l’homme,11, 448–453.Google Scholar
- 20.Zaslow J., Rosenthal A., (1954): Ann. Surg. The Excretion and Concentration of Terramycin in the Abnormal Human Biliary Tract,139, 478–483.Google Scholar
- 21.Rundle F.F., Cass M.H., Robson B., Middleton M., (1955): Surgery. Bile drainage after cholecystectomy in man, with some observations on biliary fistula,37, 903–910.Google Scholar
- 22.Meyers W.C. (1986): in Textbook of Surgery. The Liver. Anatomy and physiology, Ed: Sabiston D.C., WB Saunders Philadelphia, 1053–1068.Google Scholar
- 23.Phillip S.F., Summerskill W.H.J., (1966): Mayo Clin. Proc. Occlusion of the jejunum for intestinal perfusion in man,41, 224–231.Google Scholar